It’s not just about plaques: rTMS also reduces cognitive and functional decline in Alzheimer’s
![](https://sinapticatx.com/wp-content/uploads/2023/07/bioworld-medtech.png)
The growing number of drugs gaining U.S. FDA approval for Alzheimer’s disease has kept their ability to reduce amyloid beta and tau proteins in the news, but the degenerative disease is not simply a matter of tangles and deposits. A loss of synaptic plasticity and disrupted neural networks underlie the signature impairment of memory and […]
Sinaptica Appoints Ken Mariash CEO
![](https://sinapticatx.com/wp-content/uploads/2023/07/Group-119.png)
Company accelerates after unprecedented positive Phase 2 data in Alzheimer’s, showing >80% disease slowing on cognitive & functional endpoints CAMBRIDGE, Mass.-– Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and neurodegenerative diseases, announces the appointment of Ken Mariash Jr. as Chief Executive Officer. […]
TMS-EEG perturbation biomarkers for Alzheimer’s disease patients classification
![](https://sinapticatx.com/wp-content/uploads/2023/05/scientific-reports-logo.png)
The combination of TMS and EEG has the potential to capture relevant features of Alzheimer’s disease (AD) pathophysiology. We used a machine learning framework to explore time-domain features characterizing AD patients compared to age-matched healthy controls (HC). More than 150 time-domain features including some related to local and distributed evoked activity were extracted from TMS-EEG […]
Repetitive TMS to the Precuneus Stabilizes Cognitive Status
![](https://sinapticatx.com/wp-content/uploads/2022/11/brain-logo.png)
This scientific commentary refers to ‘Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial’ by Koch et al. (https://doi.org/10.1093/brain/awac285). Neurodegenerative dementia, in particular Alzheimer’s disease, is a global crisis with no existing cure. Technologies targeting neuroplasticity of the brain offer hope for slowing disease progression, avoiding further decline, and even reversing the decline that […]
Noninvasive Brain Stimulation Shows Potential
![](https://sinapticatx.com/wp-content/uploads/2022/11/neurology-live-logo-1.png)
Noninvasive Brain Stimulation Shows Potential to Slow Cognitive and Functional Decline in Mild-to-Moderate Alzheimer Disease Patients treated with PC-rTMS showed almost no decline in the CDR-SB score, and presented a clear advantage in terms of cognitive functions in contrast to the worsening of the score observed in the sham group. Findings from a 24-week phase […]
Positive Phase II Alzheimer’s trial results Published
![](https://sinapticatx.com/wp-content/uploads/2022/11/brain-logo.png)
Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease Phase II sham-controlled randomized trial met its primary endpoint with statistical significance; treatment slowed cognitive decline by 82% over 6 months in the treated population compared to sham with no safety issues […]
FDA breakthrough device designation stimulates increased interest
![](https://sinapticatx.com/wp-content/uploads/2023/07/bioworld-medtech.png)
Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough device designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, brain wave monitoring, and artificial intelligence (AI) to address the cognitive and functional decline in patients with neurological disorders. “We are excited that the FDA has recognized the groundbreaking potential of our SinaptiStim–AD System with […]
Sinaptica featured on Mass Device
![](https://sinapticatx.com/wp-content/uploads/2022/10/mass-device-logo-1.png)
Sinaptica’s neurostim treatment for Alzheimer’s wins FDA Breakthrough nod Sinaptica Therapeutics announced today that it received FDA breakthrough device designation for its investigational SinaptiStim AD system. Cambridge, Massachusetts-based Sinaptica designed its system to treat cognitive and functional decline in patients diagnosed with Alzheimer’s disease (AD). The system creates a novel integration of neurostimulation and brain […]
Sinaptica FDA Breakthrough Device Designation
![](https://sinapticatx.com/wp-content/uploads/2022/10/WhatsApp-Image-2023-08-02-at-16.21.45.jpeg)
Sinaptica Therapeutics Announces FDA Breakthrough Device Designation for its Novel Noninvasive Neurostimulation Treatment for Alzheimer’s Disease SinaptiStim™ – AD System provides personalized and precision-delivered electromagnetic therapeutic approach to treating cognitive and functional decline in Alzheimer’s disease patients Breakthrough designation is based on positive outcomes from a Phase II clinical trial in mild-to- moderate Alzheimer’s disease […]